Editas Medicine, Inc.

EDIT Healthcare Biotechnology

Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.

2.47 0.28 −10.18%
Market cap
$422.3M
P/E
0.0×
Fwd P/E
−2.7×
Dividend yield
—
F-score
2/9
Altman Z
−13.39
Beneish M
−2.46
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 4 2 3

+8 more TTM periods

ROE
(118.82%) (326.07%) (198.14%) (211.37%)
ROA
(33.02%) (52.76%) (60.61%) (75.51%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(48.58%) (119.51%) (132.07%) (167.36%)
Average Days of Receivables
21.16 24.45 136.70 63.98
Free Cash Flow per Share
(1.01) (1.44) (1.87) (2.00)
Free Cash Flow
(120.28) (140.66) (165.58) (180.55)
Other line items

Show all line items

Columns are period end dates